diluents, adjuvants, excipients or any combination thereof, the *Cannabis* extract comprising a cannabinoid fraction comprising Δ^9-Tetrahydrocannabinol (THC), Cannabidiol (CBD), and Cannabinol (CBN), and a terpene fraction in an amount of at least 3% by weight of the extract.

[0006b] In another aspect, the present disclosure refers to a medicament comprising an effective amount of the pharmaceutical composition as disclosed herein.

[0006c] In another aspect, the present disclosure refers to a use of an effective amount of the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treating a sleep disorder.

[0006d] In yet another aspect, the present disclosure refers to a use of a *Cannabis* extract in the preparation of a medicament for treating a sleep disorder, wherein the *Cannabis* extract comprises a cannabinoid fraction comprising Δ^9-Tetrahydrocannabinol (THC), Cannabidiol (CBD) and Cannabinol (CBN), and a terpene fraction in an amount of at least 3% by weight of the extract.

[0007] In a further example, there is provided use of the *Cannabis* extract in the preparation of a medicament for treating a sleep disorder.

Claims

1. A pharmaceutical composition comprising a *Cannabis* extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the *Cannabis* extract comprising a cannabinoid fraction comprising Δ^9-Tetrahydrocannabinol (THC), Cannabidiol (CBD), and Cannabinol (CBN), and a terpene fraction in an amount of at least 3% by weight of the extract.

2. The pharmaceutical composition of claim 1, comprising THC in an amount from 5% to 90% by weight of the extract.

3. The pharmaceutical composition of claim 1 or 2, comprising CBD in an amount from 1% to 20% by weight of the extract.

4. The pharmaceutical composition of any one of claims 1 to 3, comprising CBN in an amount from 1% to 20% by weight of the extract.

5. The pharmaceutical composition of any one of claims 1 to 4, wherein the terpene fraction comprises one or more of linalool, myrcene, and nerolidol.

6. The pharmaceutical composition of any one of claims 1 to 5, wherein the terpene fraction comprises beta-myrcene in an amount from 1% to 50% by weight of the terpene fraction.

7. The pharmaceutical composition of any one of claims 1 to 6, wherein the THC is a main cannabinoid.

8. The pharmaceutical composition of any one of claims 1 to 7, wherein the ratio of THC:CBN is from 5:1 to 20:1.

9. The pharmaceutical composition of any one of claims 1 to 8, wherein the ratio of THC:CBD is from 10:1 to 50:1.

10. The pharmaceutical composition of any one of claims 1 to 9, wherein the *Cannabis* extract is a *Cannabis* oil.

11. The pharmaceutical composition of any one of claims 1 to 10, wherein the *Cannabis* extract comprises the terpene fraction in an amount of less than 50% by weight of the extract.

12. The pharmaceutical composition of any one of claims 1 to 11, wherein the ratio of the cannabinoid fraction:terpene fraction is from 8:1 to 33:1.

13. The pharmaceutical composition of any one of claims 1 to 11, for treating a sleep disorder.

14. A medicament comprising an effective amount of the pharmaceutical composition of any one of claims 1 to 12.

15. Use of an effective amount of the pharmaceutical composition of any one of claims 1 to 12 in the manufacture of a medicament for treating a sleep disorder.

16. Use of a *Cannabis* extract in the preparation of a medicament for treating a sleep disorder, wherein the *Cannabis* extract comprises a cannabinoid fraction comprising Δ^9-Tetrahydrocannabinol (THC), Cannabidiol (CBD) and Cannabinol (CBN), and a terpene fraction in an amount of at least 3% by weight of the extract.